Low Sulfur Fecal Transplant for Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

Low Sulfur Fecal Transplant for Ulcerative Colitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03948919
• Other study ID #: GI-2019-27285
• Status: Completed
• Phase: Phase 1
• Start date: July 31, 2019
• Est. completion date: January 4, 2024

Study information

• Verified date: March 2024
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the engraftment of donor microbiota's sulfate reducing bacteria (SRB) in subjects with active ulcerative colitis (UC) following sequential fecal microbiota transplant (FMT). Specifically this study will evaluate if low SRB donor microbiota translates to lower SRB microbiota in the UC recipient. It is widely unknown if the microbiota in UC is dysfunctional and therefore perpetuates inflammation, or if the ongoing inflammation shapes the microbiota. Patients with UC have a higher relative abundance of SRB compared to healthy controls. It is the aim of this study to determine if the microbiota in UC can be altered to favor a low SRB fraction.

Description:

Inflammatory bowel disease (IBD) is a chronic, relapsing remitting inflammatory disease of the intestine. The two main forms of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). There is no cure for IBD and the etiology is unknown, however IBD is thought to arise as an aberrant immune response to the intestinal microbiota. The intestinal microbiota closely correlates with inflammation in IBD. Currently, the treatment of IBD is based on suppressing the aberrant immune response in the intestine. This often takes the form of systemic immunosuppression, which in turn carries a multitude of risks including infection and malignancy. Thus there is an urgent need for safe, effective therapies that ultimately have the potential to cure IBD.

Fecal microbiota transplantation (FMT) is the process of transferring fecal microbiota from one individual to another. FMT has revolutionized the treatment of multiple recurrent Clostridium difficile infection with a cure rate around 90%. Given the success of FMT in C. difficile colitis, attention turned to other forms of colitis, in particular IBD. Early pilot studies demonstrated a mixed result for the use of FMT in IBD. One of the key issues surrounding the use of FMT in IBD is the challenge of engrafting a new microbiota. Additionally IBD flares following FMT for C. difficile infection have been reported, although it is difficult to account for the confounding of the underlying C. difficile infection. This study will examine how FMT donor selection can impact the engraftment of the microbiota into patients with UC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: January 4, 2024
• Est. primary completion date: November 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Able and willing to provide consent

• English speaking

• Diagnosis of ulcerative colitis based on typical clinical-histopathic diagnosis

• Diagnosis of ulcerative colitis > 3 months

• Active disease on endoscopy (endoscopic Mayo subscore = 1)

• Evidence of inflammation extending beyond a minimum of 20cm

• Any ongoing ulcerative colitis therapy must be at stable doses for 4 weeks prior to study and remain stable over the course of the study

Exclusion Criteria:

• Extensive bowel resection

• Presence of ileostomy or colostomy

• Suspicion of ischemic colitis, radiation colitis or microscopic colitis

• Diagnosis of Crohn's disease

• Diagnosis of per-anal fistula or abscess

• Adenomatous polyps that have not been removed

• Use of pre or probiotics within 30 days of randomization

• Pregnancy

• Severe food allergies

• End stage liver disease or cirrhosis

• An absolute neutrophil count < 500 cell/µL

• Life expectancy < 6 months

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• Fecal microbiota
Lyophilized encapsulated fecal microbiota given daily for 8 weeks.

Other:
• Placebo
Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Engraftment of low sulfate reducing microbiota	Change in quantitative PCR of sulfate reducing genes from baseline to week 12 between FMT arm and placebo arm.	12 weeks
Secondary	Rate of change of sulfate reducing microbiota	Change in quantitative PCR of sulfate reducing genes at week 1, 2, 3 and 4 between FMT arm and placebo arm	4 weeks
Secondary	Clinical efficacy of FMT versus placebo	Change in partial Mayo score from baseline to week 8 between FMT and placebo arm	8 weeks
Secondary	Clinical efficacy of low sulfate reducing microbiota	Partial mayo score at week 12 between those with low sulfate reducing microbiota or not low sulfate reducing microbiota	12 weeks
Secondary	Serious adverse events	Number of serious adverse events between FMT arm and placebo arm	12 weeks